GCP
DAWN

GSA Capital Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

GSA Capital Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-142,809
Closed -$1.33M – 1813
2025
Q4 		$1.33M Buy
+142,809
New +$1.19M 0.11% 220
2025
Q3 		– Sell
-63,546
Closed -$413K – 1731
2025
Q2 		$413K Buy
63,546
+19,843
+45% +$137K 0.03% 1048
2025
Q1 		$347K Sell
43,703
-54,327
-55% -$585K 0.03% 1044
2024
Q4 		$1.24M Buy
98,030
+38,771
+65% +$539K 0.09% 268
2024
Q3 		$825K Buy
+59,259
New +$845K 0.06% 591
2024
Q1 		– Sell
-30,378
Closed -$444K – 1686
2023
Q4 		$444K Buy
+30,378
New +$368K 0.04% 872
2023
Q2 		– Sell
-36,494
Closed -$488K – 1591
2023
Q1 		$488K Buy
+36,494
New +$713K 0.05% 734

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

GSA Capital Partners's DAWN Position: Q1 2026 in Review

GSA Capital Partners sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 142,809 shares — an estimated $1.33M sold.

GSA Capital Partners first reported a position in DAWN in Q1 2023 and held it in 7 quarters. The position peaked at $1.33M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • GSA Capital Partners reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 142,809 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.33M.
  • GSA Capital Partners first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 7 quarters.
  • GSA Capital Partners's Day One Biopharmaceuticals position peaked at $1.33M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.